Decoding the Structural Basis For Carbapenem Hydrolysis By Class A β-lactamases: Fishing For A Pharmacophore

Current Drug Targets

Volumn 17, Issue 9, 2016, Pages 983-1005

  Tondi, Donatella ^a   Cross, Simon ^b   Venturelli, Alberto ^c   Costi, Maria P ^a   Cruciani, Gabriele ^d   Spyrakis, Francesca ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Molecular Discovery Limited   (United Kingdom)

^c Tydock Pharma   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Carbapenemases; Guyana extended spectrum lactamase (GES); Klebsiella pneumoniae carbapenemase (KPC); Molecular interaction fields (MIFs); Nonmetallo carbapanemase (NMC); Pharmacophore prediction; Serratia fonticola (SFC1); Serratia marcescens (SME)

Indexed keywords

3 NITROPHENYL BORONIC ACID; AMOXICILLIN; AMPICILLIN; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN; CITRIC ACID; CLAVULANIC ACID; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; PROTEIN GES 5; PROTEIN KPC 2; PROTEIN NMC A; PROTEIN SFC 1; PROTEIN TEM1; SULBACTAM; TAZOBACTAM; TICARCILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CARBAPENEM DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CRYSTAL STRUCTURE; DEACYLATION; DRUG DESIGN; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HYDROGEN BOND; HYDROLYSIS; PHARMACOPHORE; PROTEIN CONFORMATION; PROTEIN INTERACTION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; BACTERIUM; CHEMISTRY; ENZYMOLOGY; METABOLISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

BACTERIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, BACTERIAL; HYDROLYSIS; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84973664420     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666151001104448     Document Type: Article

References (136)

1. Pitout JD, Laupland KB. Extended-spectrum β-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
2. Pitout JD. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 2008; 6: 657-69.
3. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistance? Focus on F-lactamases. Drug Resist Updat 2006; 9: 142-56.
4. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000; 3: 489-95.
5. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrugresistant gram-negative bacilli in North America. Pharmacotherapy 2008; 28: 235-49.
6. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45: 1179-81.
7. Patel G, Bonomo RA. "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 2013; 4: 48.
8. Sougakoff W, L'Hermite G, Pernot L, et al. Structure of the imipenem-hydrolyzing class A i-lactamase SME-1 from Serratia marcescens. Acta Crystallogr D Biol Crystallogr 2002; 58: 267-74.
9. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 2012; 18: 263-72.
10. Coulthurst SJ, Barnard AM. Salmond GP. Regulation and biosynthesis of carbapenem antibiotics in bacteria. Nat Rev Microbiol 2005; 3: 295-306.
11. El-Gamal MI, Oh CH. Current status of carbapenem antibiotics. Curr Top Med Chem 2010; 10: 1882-97.
12. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008; 9: 23-37.
13. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011; 55: 4943-60.
14. th Interscience Conference on Antimicrobial Agents and Chemotherapy 1986. American Society for Microbiology, Washington DC, 1986; p. 117.
15. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J Antimicrob Chemother 2007; 60: 470-82.
16. Drekonja DM, Beekmann SE, Elliott S, et al. Challenges in the management of infections due to carbapenem-resistant Enterobacteriaceae. Infect Control Hosp Epidemiol 2014; 35: 437-9.
17. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007; 20: 440-58.
18. Livermore DM, Woodford N. The o-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 413-20.
19. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006; 34: S20-8; discussion S64-73.
20. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010; 54: 969-76.
21. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 2013; 44: 51-6.
22. Pogue JM, Marchaim D, Kaye D, Kaye KS. Revisiting "older" antimicrobials in the era of multidrug resistance. Pharmacotherapy 2011; 31: 912-21.
23. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39: 283-94.
24. Boucher HW, Talbot GH, Benjamin DK, et al. for the Infectious Diseases Society of America 10 Ã- '20 Progress-development of new drugs active against gram-negative bacilli: An update from the infectious diseases society of america. Clin Infect Dis 2013; 56: 1685-94.
25. OMS. Antimicrobial resistance: global report on surveillance 2014. Available at: http://apps.who.int/iris/bitstream/10665/112642/1/97 89241564748_eng.pdf.
26. Ambler RP, Coulson AF, Frere JM, et al. A standard numbering scheme for the class A s-lactamases. Biochem J 1991; 276 (Pt 1): 269-70.
27. Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases. J Antimicrob Chemother 2006; 57: 373-83.
28. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
29. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010; 36 (Suppl 3): S8-14.
30. Patel G, Bonomo RA. Status report on carbapenemases: challenges and prospects. Expert Rev Anti Infect Ther 2011; 9: 555-70.
31. Farina D, Spyrakis F, Venturelli A, Cross S, Tondi D, Costi MP. The inhibition of extended spectrum T-lactamases: hits and leads. Curr Med Chem 2014; 21: 1405-34.
32. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
33. English AR, Retsema JA, Girard AE, Lynch JE, Barth WE. CP-45, 899, a 8-lactamase inhibitor that extends the antibacterial spectrum of o-lactams: initial bacteriological characterization. Antimicrob Agents Chemother 1978; 14: 414-9.
34. Frase H, Smith CA, Toth M, Champion MM, Mobashery S, Vakulenko SB. Identification of products of inhibition of GES-2 S- lactamase by tazobactam by x-ray crystallography and spectrometry. J Biol Chem 2011; 286: 14396-409.
35. Frase H, Toth M, Champion MM, Antunes NT, Vakulenko SB. Importance of position 170 in the inhibition of GES-type I- lactamases by clavulanic acid. Antimicrob Agents Chemother 2011; 55: 1556-62.
36. Swaren P, Maveyraud L, Raquet X, et al. X-ray analysis of the NMC-A N-lactamase at 1.64-A resolution, a class A carbapenemase with broad substrate specificity. J Biol Chem 1998; 273: 26714-21.
37. Naas T, Nordmann P. Analysis of a carbapenem-hydrolyzing class A A-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. Proc Natl Acad Sci USA 1994; 91: 7693-7.
38. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for a-lactams? Lancet Infect Dis 2011; 11: 381-93.
39. Palzkill T. Metallo-β-lactamase structure and function. Ann NY Acad Sci 2013; 1277: 91-104.
40. Bou G, Santillana E, Sheri A, et al. Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J Am Chem Soc 2010; 132: 13320-31.
41. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67: 1597-606.
42. Docquier JD, Calderone V, De Luca F, et al. Crystal structure of the OXA-48 t-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol 2009; 16: 540-7.
43. Santillana E, Beceiro A, Bou G, Romero A. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci USA 2007; 104: 5354- 9.
44. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr Opin Pharmacol 2007; 7: 459-69.
45. Bush K, Mobashery S. How. -lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. Adv Exp Med Biol 1998; 456: 71-98.
46. Matagne A, Lamotte-Brasseur J, Frere JM. Catalytic properties of class A c-lactamases: efficiency and diversity. Biochem J 1998; 330 (Pt 2): 581-98.
47. Hardy LW, Kirsch JF. Isolation of a Staphylococcus aureus β-lactamase-dicloxacillin complex and kinetic studies on the reactivation of the enzyme. Arch Biochem Biophys 1989; 268: 338-48.
48. Kalp M, Carey PR. Carbapenems and SHV-1 β-lactamase form different acyl-enzyme populations in crystals and solution. Biochemistry 2008; 47: 11830-7.
49. Maveyraud L, Pratt RF, Samama JP. Crystal structure of an acylation transition-state analog of the TEM-1 a-lactamase. Mechanistic implications for class A i-lactamases. Biochemistry 1998; 37: 2622-8.
50. Nukaga M, Bethel CR, Thomson JM, et al. Inhibition of class A I- lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J Am Chem Soc 2008; 130: 12656-62.
51. Nordmann P, Mariotte S, Naas T, Labia R, Nicolas MH. Biochemical properties of a carbapenem-hydrolyzing p-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrob Agents Chemother 1993; 37: 939-46.
52. Felici A, Perilli M, Segatore B, et al. Interactions of biapenem with active-site serine and metallo-a-lactamases. Antimicrob Agents Chemother 1995; 39: 1300-5.
53. Boyer-Mariotte S. Enzymatic resistance to imipenem in gramnegative bacilli: NMC-A, an original carbapenemase. Ann Pharm Fr 1998; 56: 244-9.
54. Raquet X, Lamotte-Brasseur J, Bouillenne F, Frere JM. A disulfide bridge near the active site of carbapenem-hydrolyzing class A b- lactamases might explain their unusual substrate profile. Proteins 1997; 27: 47-58.
55. Banerjee S, Pieper U, Kapadia G, Pannell LK, Herzberg O. Role of the omega-loop in the activity, substrate specificity, and structure of class A o-lactamase. Biochemistry 1998; 37: 3286-96.
56. Huletsky A, Knox JR, Levesque RC. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type i-lactamases probed by site-directed mutagenesis and threedimensional modeling. J Biol Chem 1993; 268: 3690-7.
57. Raquet X, Lamotte-Brasseur J, Fonze E, Goussard S, Courvalin P, Frere JM. TEM F-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis. J Mol Biol 1994; 244: 625-39.
58. Maveyraud L, Massova I, Birck C, Miyashita K, Samama JP, Mobashery S. Crystal Structure of 6α-(Hydroxymethyl) penicillanate Complexed to the TEM-1 β-Lactamase from Escherichia coli: Evidence on the mechanism of action of a novel inhibitor designed by a computer-aided process. J Am Chem Soc 1996; 118: 7435-646.
59. Miyashita K, Massova I, Mobashery S. Quantification of the extent of attenuation of the rate of turnover chemistry of the TEM-1 α- lactamase by the α-1R-hydroxyethyl group in substrates. Bioorg Med Chem Lett 1996; 6: 319-322.
60. Mariotte-Boyer S, Nicolas-Chanoine MH, Labia R. A kinetic study of NMC-A o-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins. FEMS Microbiol Lett 1996; 143: 29-33.
61. Mourey L, Miyashita K, Swaren P, Bulychev A, Samama JP, Mobashery S. Inhibition of the NMC-A M-lactamase by a penicillanic acid derivative and the structural bases for the increase in substrate profile of this antibiotic resistance enzyme. J Am Chem Soc 1998; 120: 9382-3.
62. Pottumarthy S, Moland ES, Juretschko S, Swanzy SR, Thomson KS, Fritsche TR. NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg Infect Dis 2003; 9: 999-1002.
63. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 2014; 44: 51-6.
64. Yang YJ, Wu PJ, Livermore DM. Biochemical characterization of a a-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother 1990; 34: 755-8.
65. Queenan AM, Torres-Viera C, Gold HS, et al. SME-type carbapenem- hydrolyzing class A h-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000; 44: 3035-9.
66. Poirel L, Wenger A, Bille J, Bernabeu S, Naas T, Nordmann P. SME-2-producing Serratia marcescens isolate from Switzerland. Antimicrob Agents Chemother 2007; 51: 2282-3.
67. 2-lactamase Sme-1 from Serratia marcescens. J Struct Biol 1996; 116: 313-6.
68. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 2006; 56: 367-72.
69. Naas T, Livermore DM, Nordmann P. Characterization of an LysR family protein, SmeR from Serratia marcescens S6, its effect on expression of the carbapenem-hydrolyzing e-lactamase Sme-1, and comparison of this regulator with other c-lactamase regulators. Antimicrob Agents Chemother 1995; 39: 629-37.
70. Fairfax MR, Queenan AM, Lephart PR, et al. Detection of 2 SME- 1 carbapenemase-producing Serratia marcescens in Detroit. Diagn Microbiol Infect Dis 2011; 71: 325-6.
71. Mataseje LF, Bryce E, Roscoe D, et al. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J Antimicrob Chemother 2012; 67: 1359-67.
72. Vourli S, Giakkoupi P, Miriagou V, Tzelepi E, Vatopoulos AC, Tzouvelekis LS. Novel GES/IBC extended-spectrum /-lactamase variants with carbapenemase activity in clinical enterobacteria. FEMS Microbiol Lett 2004; 234: 209-13.
73. Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extendedspectrum s-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 2000; 44: 622- 32.
74. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A P-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 2001; 45: 2598-603.
75. Strynadka NC, Adachi H, Jensen SE, et al. Molecular structure of the acyl-enzyme intermediate in t-lactam hydrolysis at 1.7 A resolution. Nature 1992; 359: 700-5.
76. Sougakoff W, Naas T, Nordmann P, Collatz E, Jarlier V. Role of ser-237 in the substrate specificity of the carbapenem-hydrolyzing class A c-lactamase Sme-1. Biochim Biophys Acta 1999; 1433: 153-8.
77. Bush K, Pannell M, Lock JL, et al. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. Int J Antimicrob Agents 2013; 41: 1-4.
78. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenemhydrolyzing N-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-61.
79. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47: 1297-300.
80. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006; 50: 3098-101.
81. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12: 223-30.
82. Hossain A, Ferraro MJ, Pino RM, et al. Plasmid-mediated carbapenem- hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother 2004; 48: 4438-40.
83. Zhang R, Zhou HW, Cai JC, Chen GX. Plasmid-mediated carbapenem- hydrolysing h-lactamase KPC-2 in carbapenem-resistant Ser ratia marcescens isolates from Hangzhou, China. J Antimicrob Chemother 2007; 59: 574-6.
84. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-36.
85. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenemresistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165: 1430-5.
86. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemaseproducing bacteria. South Med J 2011; 104: 40-5.
87. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase and metallo-g- lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008; 52: 570-3.
88. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010; 36 (Suppl 2): S50-4.
89. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-9.
90. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010; 65: 1807-18.
91. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase- producing K. pneumoniae. Infect Control Hosp Epidemiol 2009; 30: 1180-5.
92. Landman D, Bratu S, Kochar S, et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 2007; 60: 78-82.
93. 2-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51: 711- 4.
94. Woodford N, Turton JF, Livermore DM. Multiresistant Gramnegative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35: 736-55.
95. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96.
96. Woodford N, Tierno PM, Jr., Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A A-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48: 4793-9.
97. Pope J, Adams J, Doi Y, Szabo D, Paterson DL. KPC type β-lactamase, rural Pennsylvania. Emerg Infect Dis 2006; 12: 1613-4.
98. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem- hydrolyzing h-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49: 4423-4.
99. Alba J, Ishii Y, Thomson K, Moland ES, Yamaguchi K. Kinetics study of KPC-3, a plasmid-encoded class A carbapenemhydrolyzing s-lactamase. Antimicrob Agents Chemother 2005; 49: 4760-2.
100. Bernstein FC, Koetzle TF, Williams GJ, et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 1977; 112: 535-42.
101. Ke W, Bethel CR, Thomson JM, Bonomo RA, van den Akker F. Crystal structure of KPC-2: insights into carbapenemase activity in class A c-lactamases. Biochemistry 2007; 46: 5732-40.
102. Tondi D, Calò S, Shoichet BK, Costi MP. Structural study of phenyl boronic acid derivatives as AmpC β-lactamase inhibitors. J Antimicrob Chemother 2010; 20: 3416-9.
103. Padayatti PS, Sheri A, Totir MA, et al. Rational design of a R- lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone. J Am Chem Soc 2006; 128: 13235-42.
104. Tondi D, Venturelli A, Bonnet R, Pozzi C, Shoichet BK, Costi, MP. Targeting Serine MMlactamases with a novel broad spectrum boronic acid. J Med Chem 2014; 57: 5449-58.
105. Tondi D, Powers RA, Caselli E, et al. Structure-based design and in-parallel synthesis of inhibitors of AmpC i-lactamase. Chem Biol 2001; 8: 593-611.
106. Venturelli A, Tondi D, Cancian L, et al. Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem 2007; 50: 5644-54.
107. Strynadka NC, Jensen SE, Alzari PM, James MN. A potent new mode of m-lactamase inhibition revealed by the 1.7 A X-ray crystallographic structure of the TEM-1-BLIP complex. Nat Struct Biol 1996; 3: 290-7.
108. Ness S, Martin R, Kindler AM, et al. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 i-Lactamase(,). Biochemistry 2000; 39: 5312- 21.
109. Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A o-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob Agents Chemother 2008; 52: 3725-36.
110. Tranier S, Bouthors AT, Maveyraud L, Guillet V, Sougakoff W, Samama JP. The high resolution crystal structure for class A S- lactamase PER-1 reveals the bases for its increase in breadth of activity. J Biol Chem 2000; 275: 28075-82.
111. Ke W, Bethel CR, Papp-Wallace KM, et al. Crystal structures of KPC-2 K-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226. Antimicrob Agents Chemother 2012; 56: 2713-8.
112. Ramos PI, Picão RC, Almeida LG, et al. Comparative analysis of the complete genome of KPC-2-producing Klebsiella pneumoniae Kp13 reveals remarkable genome plasticity and a wide repertoire of virulence and resistance mechanisms. BMC Genomics 2014; 15: 54.
113. Naas T, Poirel L, Nordmann P. Minor extended-spectrum β-lactamases. Clin Microbiol Infect 2008; 14 (Suppl 1): 42-52.
114. Giakkoupi P, Tzelepi E, Tassios PT, Legakis NJ, Tzouvelekis LS. Detrimental effect of the combination of R164S with G238S in TEM-1 T-lactamase on the extended-spectrum activity conferred by each single mutation. J Antimicrob Chemother 2000; 45: 101-4.
115. Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS. An integron-associated -lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum i- lactamase IBC-1. J Antimicrob Chemother 2001; 48: 627-30.
116. Wachino J, Doi Y, Yamane K, et al. Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A a- lactamase, GES-4, possessing a single G170S substitution in the omega-loop. Antimicrob Agents Chemother 2004; 48: 2905-10.
117. Smith CA, Caccamo M, Kantardjieff KA, Vakulenko S. Structure of GES-1 at atomic resolution: insights into the evolution of carbapenamase activity in the class A extended-spectrum a- lactamases. Acta Crystallogr D Biol Crystallogr 2007; 63: 982-92.
118. Bae IK, Lee YN, Jeong SH, et al. Genetic and biochemical characterization of GES-5, an extended-spectrum class A o-lactamase from Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2007; 58: 465-8.
119. Smith CA, Frase H, Toth M, et al. Structural basis for progression toward the carbapenemase activity in the GES family of t- lactamases. J Am Chem Soc 2012; 134: 19512-5.
120. Delbruck H, Bogaerts P, Kupper MB, et al. Kinetic and crystallographic studies of extended-spectrum GES-11, GES-12, and GES- 14 1-lactamases. Antimicrob Agents Chemother 2012; 56: 5618- 25.
121. Bebrone C, Bogaerts P, Delbruck H, et al. GES-18, a new carbapenem- hydrolyzing GES-Type h-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues. Antimicrob Agents Chemother 2013; 57: 396-401.
122. Poirel L, Brinas L, Fortineau N, Nordmann P. Integron-encoded GES-type extended-spectrum G-lactamase with increased activity toward aztreonam in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3593-7.
123. Healey WJ, Labgold MR, Richards JH. Substrate specificities in class A c-lactamases: preference for penams vs. cephems. The role of residue 237. Proteins 1989; 6: 275-83.
124. Majiduddin FK, Palzkill T. Amino acid residues that contribute to substrate specificity of class A e-lactamase SME-1. Antimicrob Agents Chemother 2005; 49: 3421-7.
125. Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS. Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES i- lactamases. Antimicrob Agents Chemother 2010; 54: 4864-71.
126. Pfyffer GE. Serratia fonticola as an infectious agent. Eur J Clin Microbiol Infect Dis 1992; 11: 199-200.
127. Fonseca F, Sarmento AC, Henriques I, et al. Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing C- lactamase. Antimicrob Agents Chemother 2007; 51: 4512-4.
128. Fonseca F, Chudyk EI, van der Kamp MW, Correia A, Mulholland AJ, Spencer J. The basis for carbapenem hydrolysis by class A A- lactamases: a combined investigation using crystallography and simulations. J Am Chem Soc 2012; 134: 18275-85.
129. Frase H, Shi Q, Testero SA, Mobashery S, Vakulenko SB. Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of i-lactamases. J Biol Chem 2009; 284: 29509-13.
130. Majiduddin FK, Palzkill T. Amino acid sequence requirements at residues 69 and 238 for the SME-1 r-lactamase to confer resistance to t-lactam antibiotics. Antimicrob Agents Chemother 2003; 47: 1062-7.
131. Cross S, Baroni M, Goracci L, Cruciani G. GRID-based threedimensional pharmacophores I: FLAPpharm, a novel approach for pharmacophore elucidation. J Chem Inf Model 2012; 52: 2587.
132. Baroni M, Cruciani G, Sciabola S, Perruccio F, Mason J. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model 2007; 47: 279.
133. Spyrakis F, Cellini B, Bruno S, et al. Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis. Chem Med Chem 2014; 9: 1501-11.
134. Spyrakis F, Singh R, Cozzini P, et al. Isozyme-specific ligands for O-acetylserine sulfhydrylase, a novel antibiotic target. PLoS One 2013; 8: e77558.
135. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28: 849-57.
136. Mourey L, Swaren P, Miyashita K, Bulychev A, Mobashery S, Samama JP. Inhibition of the Nmc-A B-lactamase by a penicillanic acid derivative, and the structural bases for the increase in substrate profile of this antibiotic resistance enzyme. J Am Chem Soc 1998; 120: 9382-3.